Lucentis has a 55% share of NRx’s and a 50% share of TRx’s, which is unchanged from the prior quarter. As a matter of policy, DNA won’t comment on the progress of the head-to-head study sponsored by NIH.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”